Evecxia Therapeutics
Evecxia Therapeutics is dedicated to helping people with mental illness lead fuller, more meaningful lives by realizing the therapeutic potential of serotonin synthesis amplification. They focus on developing novel drug delivery technologies to amplify brain serotonin production, aiming to treat various mental health disorders such as depression, OCD, and suicidal ideation. Their approach involves proprietary pharmaceutical technologies to enable sufficient and sustained 5-HTP plasma exposure, which is the natural precursor to serotonin, to enhance endogenous serotonin synthesis and activity.
Industries
Nr. of Employees
small (1-50)
Evecxia Therapeutics
Products
Oral gastroretentive sustained-release 5-HTP tablet with low-dose peripheral decarboxylase inhibitor
An oral, gastroretentive swelling tablet designed to remain in the stomach and deliver sustained-release 5-hydroxytryptophan to the upper intestine together with a low-dose peripheral aromatic amino acid decarboxylase inhibitor to increase systemic bioavailability and enable sustained plasma exposure.
Intravenous infusion formulation of 5-HTP for acute administration
A parenteral infusion formulation designed to achieve rapid and sustained plasma exposure of the active precursor, intended for in-clinic administration as a rescue therapy with fast onset.
Oral gastroretentive sustained-release 5-HTP tablet with low-dose peripheral decarboxylase inhibitor
An oral, gastroretentive swelling tablet designed to remain in the stomach and deliver sustained-release 5-hydroxytryptophan to the upper intestine together with a low-dose peripheral aromatic amino acid decarboxylase inhibitor to increase systemic bioavailability and enable sustained plasma exposure.
Intravenous infusion formulation of 5-HTP for acute administration
A parenteral infusion formulation designed to achieve rapid and sustained plasma exposure of the active precursor, intended for in-clinic administration as a rescue therapy with fast onset.
Expertise Areas
- Clinical trial management (Phase 1 SAD/MAD)
- Translational neuropharmacology
- Formulation design for GI-targeted sustained release
- Intravenous infusion formulation for acute care
Key Technologies
- Gastroretentive sustained-release oral delivery
- Intravenous infusion formulation technology
- Small-molecule API chemical synthesis
- GLP toxicology studies